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INTRODUCTION 
 
Stroke is a worldwide concern. Approximately two hundred lakh people every 
year will suffer from stroke and of these fifty lakh will not survive
2,3
. In the developed 
nations, stroke is the leading cause for disability, second cause of dementia and third 
cause of death. Stroke is the second common cause of death and fourth leading cause 
of  disability globally
1 
.Stroke is an important cause for epilepsy, falls & depression in 
developed nations
4
 and is a leading cause of functional impairments, with 20% of 
survivors  required hospital and nursing care for a prolonged period more then 3 
months duration and 15% - 30% of patient develop permanent disability
5
.Stroke is a 
life-changing both financially  and physically. Stroke is not only a traumatic 
experience to the patients but for their near and dear ones. 
Global Stroke estimates: 
 400-800 strokes per 100,0006  
 57 lakh Deaths7 
 160 lakhs new acute strokes every year1 
 28,500,000 DALYs (disability adjusted life-year)8 
 28-30 day case fatality ranges from 17%-35%Stroke9 
Morbidity and Mortality in India 
 Prevalence 90-222 per 100,0002 
 102, 620  deaths 10 
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Morbidity and Mortality in India (continued) 
 14,40,000-16,00,004 cases of new acute strokes per year 11,12  
 6,398,000 DALY’s13  
 12 percentage of strokes occur in the population aged <40 years 14 
 28-30 day case fatality ranges from eighteen to forty one percentage2,3  
A stroke is caused by acute interruption of blood supply to the brain region it 
supplies, usually because of a blood vessel bursts or blocked by a thrombus or emboli. 
This cuts off the supply of vital oxygen and nutrients to the brain, accumulation of 
free radicals causing damage to the brain tissue. An acute total occlusion of the 
vessels to the brain can cause death of the brain tissue within four to ten minutes. The 
WHO clinically defines ―stroke as the rapid development of clinical signs and 
symptoms of a focal neurological disturbance lasting more than 24 hours or leading to 
death with no apparent cause other than vascular origin ―11.  Among CVA the 
Ischemic strokes constitutes 50%–85%.9 Hemorrhagic strokes–Subarachnoid 
hemorrhage and intra-cerebral hemorrhage, account for 1%-7% and 7%-27% 
respectively of all strokes worldwide.
9
 In a study done which is tabulated below, 
hemorrhagic stroke have significantly higher mortality when compared with ischemic 
stroke. 
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TABLE 1: Death rate (in percentage) @ One month, One year, and Five years 
after stroke  
Source: 
15
 
 1 Month 1 Year 5 Years 
Ischaemic stroke  10 23 52 
Intra-cerebral hemorrhage 
52 62 70 
Subarachnoid haemorrhage  45 
48  52 
 
 
TABLE 2: TOAST CLASSIFICATION 
TOAST  Classification  Of  Subtypes  Of  Acute  Ischemic  Stroke 
 Large Vessel atherosclerosis (emboli/thrombus) 
 Cardioembolic stroke 
 Small-vessel occlusion(lacunar infarcts) 
 Stroke related to other determined etiology 
 Stroke - undetermined etiology 
a. Two or more causes identified 
b. Negative evaluation 
                     c. Incomplete evaluation 
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TABLE 3: National  Institute  of  Health  stroke  scale ( NIHSS) 
 
NIHSS  Severity of stroke 
0 Nil symptoms 
1-4 Minor  Stroke 
5-15 Moderate  Stroke 
16-20 Moderate  to  Severe  Stroke 
21-42 Severe  Stroke 
 
 
 
In a study conducted in west China in 2012 which was later published in AHA, 
American heart study compared and analysed the anterior circulation involvement 
with the posterior circulation strokes.This study compared, the frequency of 
symptoms and signs associated with the 2 major vascular territories. Among the study 
population of 1174 consecutive patients with a diagnosis of posterior  circulation (PC) 
involvement or anterior circulation (AC) involvement which was confirmed by 
magnetic resonance imaging in the Chengdu Stroke Registry. There was 302 posterior 
and the remaining 872 anterior circulation strokes. Homolateral hemiplegia (PC, 
53.6% versus AC, 74.9%), central facial/lingual palsy (PC, 40.7% versus AC, 62.2%), 
and hemisensory deficits (PC, 36.4% versus AC, 34.2%) were the 3 most common 
symptoms and signs in PC and AC. 
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The signs with high specificity involving PC strokes were Horner’s syndrome 
(PC 4.0% versus AC 0%), crossed sensory deficits (3.0% versus 0%;), quadrantanopia 
(1.3% versus 0%),  oculomotor nerve palsy (4.0% versus 0%), and crossed motor 
deficits (4.0% versus 0.1%).In short MRI and other radiological imaging modalities 
was the key determining factors which helped in differentiating between the two 
different vascular territories.
80
 
 
In another study conducted in National Cardiovascular CenterJapan among 
ischemic stroke patients,comparing the NIHSS and the clinical outcome using 
modified Rankins scale score < 2 at 3 months.Of 302 patients studied, NIHSS at 
baseline was correlated with the favorable outcome. NIHSS ≤5  for patients with 
posterior circulation stroke (sensitivity, 84%; specificity, 81%) and ≤8 for patients 
with anterior circulation stroke (sensitivity, 80%; specificity, 82%).
16
 
 
Brain imaging plays a pivotal role in diagnosis, prognosis,management of stroke 
patients.  Various modalities of imaging such as  
 
 CT scan, CT angiography, CT perfusion studies 
 
 MRI,MRA,MRI – DWI, MRI-PWI 
 
 Carotid and vertebral duplex, transcranial Doppler (TCD), combined duplex 
and TCD 
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The sensitivity of standard noncontrast CT for brain ischemia increases after 24 
hours. The presence of early signs in CT such as infarction implies a worse prognosis.  
The presence of the followingsigns is associated with an increased risk and poor 
prognosis
17
   
 
Early signs of infarction include the following: 
 
 Hypo attenuation of one-third or more of  MCA 
 
 Obliteration of  Lentiform nucleus 
 
 Cortical sulcal effacement 
 
 Focal parenchymal hypo attenuation 
 
 Loss of the insular ribbon or obscuration of the Sylvian fissure 
 
 Hyperdense MCA sign 
 
 Loss of gray-white matter differentiation in basal ganglia18,19,20,21 
 
 
MRI have certain caveats such as takes time and not readily available  like CT 
but have significantly higher sensitivity and specificity in the diagnosis of acute 
infarction in the first few hours after onset.
22
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 Diffusion-weighted imaging (DWI) / ADC: 
   
Diffusion restriction may be seen within minutes following the onset of 
Ischemia correlates well with infarct core for a detailed discussion of DWI and ADC 
in stroke. 
 
 T2-weighted imaging and FLAIR: 
 
Less sensitive than DWI in the first few hours  
Parenchymal change loss of normal signal void in large arteries may be visible 
immediately after 6-12 hours infarcted tissue becomes high signal.  
Sulcal effacement and mass effect develop and become maximal in the first few days. 
 
 T1 
 
Low intensity roughly mirrors high T2 / FLAIR signal  
Cortical laminar necrosis or pseudolaminar necrosis may be seen as a ribbon of 
intrinsic high T1 signal, usually after 2 weeks (although it can be seen earlier). 
 
 SWI: 
 
Highly sensitive in the detection of haemorrhage
 22,23,24 
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Figure 1 
 9 
 
Figure 2 
 10 
 
Figure 3 
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Figure 4:  
Crude prevalence rates for stroke Rural India 1970-2004 Vs. Urban India 1973-
2004  
 
                                                                                                 
 
 
 
AIMS  AND  OBJECTIVES: 
 Percentages of intracranial , extracranial or both involvement in stroke 
 
 Percentages of anterior and posterior circulation strokes in PSGIMSR 
 
 Most commonly involved arteries 
 
 Correlation of infarcted area in the brain and MRA + CV doppler 
 
 The acute, chronic or both nature of the brain infarcts 
 
RURAL URBAN 
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 Correlation of clinical presentations and infarcted areas 
 
 Percentages of recurrent CVA 
 
 Percentages of intracranial anomalies 
 
 Percentage of thrombolysis in PSGIMSR 
 
 NIHSS comparisons between right and the left sided brain involvement 
 
 Percentage of smokers, alcoholics or both  
 
 Percentages of DM, SHT, Dyslipidemia  
 
 Incidental ANA-IF positivity and hyperhomocystenemias in PSGIMSR 
 
 Decision regarding medical or surgical treatment based on the arterial studies 
 
 Prevention of  strokes 
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MATERIALS  AND  METHODOLOGY 
Type  of  study: Prospective  and  clinical  study 
Duration  Of  Study: One year (June 2015 – June 2016) 
Sample : 75 patients 
Study volunteers - specific population & age group :  
 
Patients between 20-80years admitted with ischemic stroke of both sexes 
 
Location: PSG Hospitals, PSGIMS&R, and Coimbatore.  
 
INCLUSION  CRITERIA: 
• Age between 20-80years 
• Patients admitted in general medical ward/neurology ward with ischemic stroke 
 
EXCLUSION  CRITERIA: 
• Age <  20years 
• Age  >  80years 
• Venous  strokes 
• Cardio embolic strokes 
 
METHODOLOGY:   
The  study  is  based  on  prospective  collection  of  data  of  patients  aged  
between 20-80 years  diagnosed  as ischemic stroke  who  got  admitted  in  medical  
ward  or  neurology  ward  in  a  tertiary  care  centre  where  systematic  computer  
coding  for  registry  is  used.  
 14 
 
 
Patients  admitted  at PSG  hospitals, PSGIMS&R, Coimbatore diagnosed  with 
ischemic stroke  confirmed  with  MRI –MRA imaging  at  admission  and  meeting  
the  inclusion  criteria  as  mentioned  above,  during  the  study  period  of  June, 2015 
to  June, 2016  are  taken  into  consideration  for  the  study.  A proforma was made  
which included detailed history, baseline NIHSS admission, clinical examination and 
requisite investigations available in the hospital. After informed consent from patients, 
history and risk factors attributable to the stroke are collected in detail. Investigations 
like complete hemogram, routine urine analysis, blood sugar, serum elecctrolytes, 
serum creatinine, blood urea, chest X-ray, FLP, ECHO, electrocardiogram, MRI –
MRA intracranium brain, CV Doppler were done in all patients. 
 
HbA1C was done if patient was found to be Diabetic based on RBS. 
Investigations like ANA- IF and serum Homocysteine was done in patients, later 
when PSG Primegrant of Rs One Lakh was awarded which I had applied earlier. 
 
Statistical tools: 
The  data  collected  from  the  patients  admitted with acute stoke and relevanr 
information was  tabulated  using  Microsoft  Excel. The patient was admitted in 
Neurology and General Medicine. The data are reported as the mean +/- SD or the 
median, depending on their distribution. Frequencies are reported / documented in 
percentages. The differences in quantitiative variables between groups were assessed 
by means of the unpaired t test. Non parametric test Wilcoxon signed test were use to 
assess the qualitative variables. To assess the difference in categoric variables 
 15 
between groups chi square test was used. Two tailed test was considered significant 
for all statistical tests when p value is <0.05. All data were analysed with a statistical 
software package (SSPS version 16.0 for microsoft windows) 
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REVIEW OF LITERATURE 
 
History and Background: 
Stroke was first recognized by Hippocratespopularly known as father of 
medicine. The oath which is often taken by the medical graduates worldwide is named 
after Hippocrates. Initially it was termed as ―apoplexy‖ in Greek language (meaning 
―struck down by violence‖). 
 
Johann Jacob Wepfer (1620–1695), the next well known person in the field of 
stroke. He studied on the corpses of deceased due to apoplexy, discovered that blood 
supply might be disrupted to the brain in the deceased either due to blocked arteries in 
few or bleed 
25 
 
Rudolf Virchow, father of modern pathology was first to describe, 
thromboembolism was a significant factor causing stroke. During nineteenth century, 
he described the term thrombosis which can detached and be mobile to form embolus 
causing cardio-embolic stroke
26
. 
 
In the year 1928, apoplexy was subcategorised based on the cause. After which 
the term cerebrovascular accident has been come into norms. Recently in 2011, use of 
this term cerebrovascular accident have been discouraged due to reasons that the word 
accident insufficiently highlights the modifiability of the underlying risk factors
27,28
. 
Now it is used as cerebrovascular incident interchangeably. 
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DEFINITION AND CLASSIFICATION : 
 
Although stroke more common in older adults, the same also occurs in lower 
incidence in neonates, infants, children and young adults age (< 40 Years), resulting in 
significant morbidity and mortality
29
. Stroke is a clinical syndrome which is classified 
broadly as: 
 
 Ischaemic strokes – These are caused by sudden occlusion of arteries supplying 
the brain, either due to thrombus or embolli intacranially or extracranilly 
causing impaired blood supply to a region of brain causing infarction. It 
accounts for 50-85% of strokes worldwide
30
. 
 Haemorrhagic strokes – defined as bleed which occurs within substance of the 
brain, intracerebral haemorrhage or contained within the subarachnoid space
31
. 
 Transient ischemic attacks (TIAs) are defined as temporary neurological 
deficit, symptoms lasting less than 24hrs. It is due to inadequate cerebral or 
ocular blood supply as a result of arterial thrombus or embolism associated 
with arterial, cardiac or hematological disease, indeed awarning for impending 
stroke. Radiologically, there is no findings in MRI or CT.
32
. 
 
Epidemiology: 
The All India registry of stroke observed that in various cities across India, 
Calcutta, Mumbai, and Trivandrum incidence of strokes were higher comparatively 
than United States (107 /100,000 per year), European population (61-111 / 100,000 
per year), Australia (99/ 100,000 year) but similar to Chinese city - Changasha. 
 18 
33,34,35,36,37
 
The crude prevalence rate was4.72 per 1,000 during the year 2003-04 in 
Calcutta. Stroke was the cause of death in 13% very similar to death due tocoronary 
artery disease (14%). The 30-day case fatality rate(CFR)  in Indian city Calcutta was 
41.08%,significantly higher when compared with Westernnations (17-33%)
33,34,35,36,37.  
This reflects poor health facilities whencompared to the western countries. 
 
Risk Factors 
They are further classified into  
 Modifiable Risks 
 Non-modifiable Risks  
 
Non modifiable risks: 
Risk factors like age, gender, race/ethinicity and family genetics come under 
non modifiable risk factors. 
1. The  male : female sex ratio among affected individuals is 7:1 in India. Among the 
females high risk groups are oral contraceptives and pregnancy.
46,47
 
2. Blacks are more commonly affected with stroke compared to whites 
3. Genetic factors for hypertension, Von Willebrand factors, Sickle cell disease 
among family may also contribute to increased risk of stroke. 
 
Modifiable risks: 
Cigarette smoking, alcohol consumption, dyslipidemia, abdominal obesity, 
Sedentary life style, Hypertension, Diabetes mellitus, OCP, pregnancy, illicit 
drugabuse, migraine headache, prior stroke or TIA. 
 19 
One interesting risk factor was previous infection with Chlamydia pneumoniae, 
raising the possibility of infection related immune reaction .
48,49
 
 
Etiology: 
A study from a hospital-based registry of Southern India has attributedmajority 
of strokes had large artery atherosclerosis, closely followed by lacunar causes and 
cardioembolic. 
 
Rare causes such as  
 Takayasusyndrome 
 MoyaMoya disease 
 Carotid dissection 
 Hyperhomocysteinemia 
 Anticardiolipin antibody 
 Protein Sdeficiency 
 Fibromuscular dysplasia 
 Radiotherapy, 
 MDS 
 Sickle cell anemia 
 Takayasu’s arteritis  
 Polyarteritisnodosa (PAN) 
 Wegener’s granulomatosis (WG) 
 Behcet’s disease 
 Amyloidangiopathy andother genetic causes. 
 20 
 
The remaining about 27% of the study population who had ischemic stroke was 
idiopathic. Among cardioembolic stroke, rheumatic heart disease (RHD) and ischemic 
heart disease (IHD) were majorcause.
38
 
 
The Indian Collaborative Acute Stroke Study (ICASS); a multicentric study 
conducted among 2,162 admitted stroke patients across southern, northern, and 
western India; observed ischemic stroke in77%, hemorrhagic stroke in 22%, and 
unspecified stroke in 1% cases based on cerebral computed tomography (CT).
39
 The 
extracranial carotid disease is the etiological factor in 25-26% and intracranial carotid 
disease in 30% of ischemic stroke cases.
40
 
 
Stroke in young 
In India, stroke below the age of 40 yrs was increasing a an alarming rate 
ranging anywhere between 15% - 30%.In a study at All India Institute of Medical 
Sciences (AIIMS), out of the 2,634 patients admitted with AIS, 440 patients (16.7%) 
were in the age group of 18-45 years and majority (83.4%) were male.
41
 The rate of 
CVT was twelve times more common in India than western nations. In a stroke study 
reported that around 50% of total strokes in young women were related to pregnancy 
& puerperium, 95% of which were due toCVT.
42
 MoyaMoya disease, not so common 
was reported in India
43
. Takayasu's arteritis
44
 is often reported in Indian population in 
both the sexes. Stroke in children and adolescents due to Takayasu's arteritis was 
reported. In another study of young patients with hemorrhagic stroke,
45
 again the 
subjects were predominantly males. The important risks in this study was 
hypertension, hypercholestremia, alcohol and anticoagulant usage. The various 
 21 
etiologies in this study were hypertension, vascular malformation, coagulopathy, 
CVT, thrombocytopenia, vasculitis, and cryptogenic stroke
45
. 
 
Table 4: Genetic causes of stroke 
TYPES: 
 
GENE 
MUTATION 
VESSEL AFFECTED 
CADASIL Notch 3 receptor Small vessel disease 
CARASIL Notch 3 receptor Small vessel disease 
Fabry disease  α‐galactosidase - A Both large and small vessel disease 
MELAS (maternal) Transfer RNA Complex 
Marfan syndrome  Fibrillin  Cardioembolism and arterial 
dissection 
Ehlers–Danlos 
syndrome – type IV 
Collagen - III  
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Figure 5: Pathophysiology of stroke 
 
 
 23 
 
 
 
 
Figure 6: Circle of Willis 
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Table 5: Common Large-Vessel Ischemic Stroke Syndromes 
 
 
 
Syndrome  Anatomy involved  Major symptoms Vessels 
involved 
Etiology 
Left MCA Left frontal/parietal 
cortex & sub cortical 
structures 
Aphasia,right visual field 
cut,motor/sensory 
deficits,face>arm>leg 
weakness;left gaze 
prefernce 
 
Left MCA or 
major 
branch,left 
ICA 
Emboli/intrinsic 
atherothrombosis 
Right 
MCA 
Right frontal/parietal 
cortex & sub cortical 
structures 
Neglect 
syndrome,agnosia,apraxia,
left motor/sensory 
deficits,visual field 
deficit,right gaze 
preference 
 
Right  MCA 
or major 
branch,Rt. 
ICA 
Same as left MCA 
Left ACA Left frontal and 
parasagittal area 
Behaviour changes,Leg> 
arm weakness,speech 
disturbances 
 
Left ACA Emboli/intrinsic 
atherothrombosis 
Right ACA Right frontal and 
parasagittal areas 
Behaviour changes,Leg> 
arm weakness 
 
Right ACA Same as left ACA 
Brainstem Pons/midbrain/medu
lla/cerebellum 
Opthalmoplegia,bilateral 
motor 
deficits,ataxia/dysmeria,na
usea,vomiting,vertigo,com
a,altered mentation 
 
Basilar artery Embolism from 
proximal 
leision/atherothro
mbosis 
PCA Upper 
midbrain/occipital 
cortex/subcortex/tha
lamus/medial 
temporal lobes 
Visual field cut,motor or 
sensory loss,seizures,gaze 
problems,CN III deficits 
PCA,thalamic 
perforators 
Embolism from 
proximal 
leision/atherothro
mbosis 
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Table 6: Common Lacunar Stroke Syndromes 
 
 
 
Syndrome  Vessels Involved Brain Location Symptoms 
Pure motor  
Hemiparesis 
 
Lenticulostriate/pontine  
Perforator 
Internal capsule, 
pons 
Unilateral 
weakness only 
Mixed 
motor/sensory 
Lenticulosriate/ 
Thalamic perforator or 
Deep white matter 
vessel 
Internal capsule, 
deep white 
matter, thalamus 
Motor and 
sensory deficits 
Pure sensory Thalamic Perforator Posterior 
thalamus 
Loss of 
contralateral 
sensory 
modalities 
 
Ataxic hemiparesis 
 
Lenticulostriate 
/basilar/pontine/ 
Perforator 
Internal capsule, 
basis pontis 
Unilateral 
weakness with 
prominent ataxia 
 
Dysarthria/clumpsy 
hand syndrome 
Lenticulostriate or deep 
white matter vessel 
Internal capsule, 
deep white 
matter 
Prominent 
dysarthria with 
isolated hand 
weakness 
 
 
Anatomy of blood vessels and clinical presentation: 
 
o ANATOMY OF CEREBRAL CIRCULATION:  
Brain is the highest perfused organ in the body. It receives about 20% of total 
circulation and also have maximum consumption of oxygen in the blood. It is 
mainly supplied by two pairs of large arteries – internal carotid arteries (ICA) and 
vertebral arteries.
78 
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Internal carotid artery(ICA) supply about 3/5
th
 of cerebrum. The two 
vertebral arteries join together to form basilar artery which supplies cerebellum 
and brain stem. These two arterial circulation join together with the help of 
communicating branches to form circle of willis.
77,79 
 
The internal carotid group produce three main vessel branches which include –   
1. Ophthalmic artery – supplies the meninges, contents of orbit. 
2. Anterior cerebral artery (ACA) – these are pair of arteries supplying the medial 
portions of frontal lobes along with prefrontal and supplementary motor cortex 
and superior medial parietal lobes. They are further subclassified into 5 smaller 
branches called callosal arteries as they also supply the carpus callosum. Due to 
collateral supply by anterior communicating artery, stroke due to ACA is very 
rare. 
o Clinical relevance –  
• Occlusion of ACA may cause following symptoms: 
• Contralateral lower limb upper motor neuron type (UMN) of weakness 
• Contralateral sensory loss in lower limb 
• Due to frontal lobe involvement – Behavioural abnormalities, cortical 
release reflexes – grasp reflex, sucking reflex, gegenhalten phenomenon. 
• Transcortical aphasia. 
 
3. Middle cerebral artery (MCA) – It also a paired artery which supplies anterior 
temporal and insular cortices. They are connected to ACA with the help of 
anterior communicating branches and connected with PCA with the help of 
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posterior communicating branches. They are further divided into 4 parts or 
segments in their course of supply. They supply the bulk of lateral surface of 
the hemispheres along with speech areas (Broca’s and Wernicke’s areas) 
o Clinical relevance –  
• Contralateral upper and lower limb UMN type of paralysis 
• Contralateral sensory loss over face and arm 
• If lenticulostriate branches of MCA are involved –  
 If involvement of dominant hemisphere  aphasia 
 Involvement of non-dominant hemisphere  contralateral 
neglect syndrome  
 
4. Posterior cerebral artery – paired arteries which supplies the posterior part 
which includes occipital lobe. It is divided into 2 branches – cortical and 
ganglionic vessels. 
 
o Clinical relevance –  
• Contralateral loss of pain and temperature 
• Contralateral homonymous hemianopia with macular sparing 
• Alexia and agraphia 
• Weber’s syndrome – 3rd  cranial nerve palsy &contralateral hemiplegia 
• Horner’s syndrome  
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Figure 7: Vascular territories of Brain 
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Table 7: PCA Syndrome: (P1 territory) 
 
Syndrome Clinical features Localization 
Claude’s Syndrome CNIII + contralateral 
ataxia 
Red nucleus / Cerebral 
penduncle 
 
Weber’s Syndrome CN III + Hemiplegia Medial mid brain /cerebral 
peduncle 
 
Benedikt’s Syndrome CN III + hemiplegia + 
ataxia 
Red nucleus / Medial mid 
brain 
 
Subthalamic Nucleus Contralateral 
hemiballismus 
 
 
Thalamic Dejerine- 
Roussy Syndrome 
Contralateral hemisensory 
loss and agonizing pain 
 
Thalamus 
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Table 8: Common Clinical findings and presentations - anatomical and vascular 
localization of Posterior Circulation 
Vascular  
territory 
Anatomical 
location 
Stroke 
syndrome 
Clinical findings 
 
Unilateral  
PCA 
 
Occipital lobe 
 
Contralateral 
homonymous 
hemianopsia 
 
Homonymous hemianopsia  
with macular sparing 
    
 Dominant occipital 
lobeplus splenium 
of corpus callosum 
Alexia without 
agraphia 
Homonymous hemianopsia 
and alexia without agraphia 
    
 Ventral occipital 
cortex; 
infracalcarine 
Achromatopsia Loss of color differentiation  
contralateral to the side of  
the lesion, can be associated 
with a quadrantanopsia 
    
 Optic radiation  
OR supracalcarine 
Inferior 
quadrantanopsia 
Inferior quadrantanopsia 
    
 Myers loop 
(temporal lobe) or 
infracalcarine 
Superior 
quadrantanopsia 
Superior quadrantanopsia 
    
Bilateral PCA Both occipital 
lobes 
Cortical 
blindness 
Bilateral cortical blindness 
 with normal phthalmological 
 findings 
    
  Anton’s 
syndrome 
Cortical blindness with denial 
 of blindness and 
confabulations or visual 
hallucinations 
    
PCA–MCA 
border zone 
regions 
Bilateral ventral–
mesial occipital–
temporal border 
zones 
Prosopagnosia Inability to recognize familiar 
 faces and/or interpret facial  
expressions. Retained ability 
to identify 
 with speech or unique feature  
(e.g., glasses, facial hair, 
tattoo, etc.) 
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 Bilateral occipital–
parietal border 
zones 
Balint’s 
syndrome 
Optic ataxia (inability to 
reach targets  with visual 
guidance), oculomotor 
apraxia  (inability to 
volitionally direct gaze), 
 and simultagnosia (inability 
to synthesize  objects within a 
visual field) 
    
 Unilateral left 
temporal–parietal 
border zone 
Transcortical 
sensory aphasia 
Impaired comprehension,  
fluent speech but preserved 
repetition 
    
PICA Inferior posterior 
cerebellar 
hemisphere, 
inferior vermis, 
lateral medulla 
Lateral medullary 
or Wallenberg 
syndrome 
Superior 
cerebellar artery 
syndrome 
Vertigo, nausea, vomiting, 
ipsilateral facial numbness 
and dysmetria, Horner’s 
syndrome,  dysphagia, and 
ataxia dysphonia  
contralateral hemisensory loss 
below the face 
    
SCA Dorsolateral upper 
brainstem and 
cerebellum and 
superior cerebellar 
peduncle 
Superior 
cerebellar artery 
syndrome 
Ipsilateral limb ataxia, 
vertigo, nystagmus, 
 dysarthria, and gait ataxia 
    
AICA Ipsilateral 
labyrinth, lateral 
pontine tegmentum 
and brachium 
pontis, ICP 
Lateral pontine 
syndrome 
Ipsilateral dysmetria, hearing 
loss,  Horner’s syndrome, 
choreiform dyskinesia,  
contralateral thermoanalgesia 
    
Top of the BA Midbrain, 
thalamus, and 
mesial temporal 
lobes and occipital 
lobes 
Top of the basilar 
syndrome 
Somnolence, peduncular 
hallucinosis,  convergence 
nystagmus, skew deviation,  
oscillatory eye movements, 
Colliers sign (retraction and 
elevation of eye lids),  
vertical gaze paralysis 
    
Mid-BA Lateral and medial 
pons 
Lateral mid-
pontine syndrome 
Ipsilateral loss of facial 
sensation and  motor function 
of the trigeminal nerve,  
ipsilateral dysmetria 
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  Medial mid-
pontine syndrome 
Ipsilateral dysmetria, 
contralateral arm  and leg 
weakness and gaze deviation 
    
Pontine 
paramedian 
penetrators 
Anteromedial pons Dorsal mid-
pontine syndrome 
Ipsilateral nuclear facial 
palsy,  horizontal gaze palsy, 
 and contralateral arm and leg 
weakness 
    
Short pontine 
circumferential 
arteries 
Anterolateral pons Superior medial 
pontine syndrome 
Ipsilateral intranuclear 
ophthalmoplegia, 
 palatal, facial, pharyngeal 
and/or  ocular myoclonus, 
dysmetria, and contralateral 
arm and leg weakness, ocular 
bobbing 
    
Proximal BA Lower pons Locked-in 
syndrome 
Quadriplegia, horizontal gaze 
paralysis,  bifacial, paralysis, 
and  tongue and mandibular 
weakness.  Awareness is 
spared 
    
VA Medulla and 
cervical spinal cord 
Medial medullary 
or Dejerine 
syndrome 
(intracranial 
disease may lead 
to Wallenberg 
syndrome) 
Contralateral arm and leg 
weakness,  hemibody loss of 
tactile, vibration,  position 
sense,  ipsilateral tongue 
paralysis 
    
Anterior spinal 
artery 
 Anterior spinal 
artery syndrome 
Quadriparesis, bilateral pain  
and temperature loss, 
decreased sphincter tone, 
 autonomic instability, and 
hyperreflexia.  
Proprioception spared 
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Table 9: Syndromes associated with respective vascular territories of Brain 
 
 
• Middle cerebral artery • Middle cerebral artery: complete 
 • Middle cerebral artery: superior division 
 • Middle cerebral artery: inferior division 
 • Gerstmann syndrome 
 • Ataxic hemiparesis 
• Posterior cerebral artery • Posterior cerebral artery: unilateral occipital 
 • Balint syndrome 
 • Cortical blindness (Anton syndrome) 
 • Weber syndrome 
 • Alexia without agraphia 
 • Thalamic pain syndrome (Dejerine–Roussy syndrome) 
• Anterior inferior cerebellar artery • Lateral pontine syndrome (Marie–Foix syndrome) 
• Posterior inferior cerebellar artery • Lateral medullary syndrome (Wallenberg syndrome) 
• Basilar artery • Locked-in syndrome 
 • Lateral pontine syndrome (Marie–Foix syndrome) 
 • Ventral pontine syndrome (Raymond syndrome) 
 • Ventral pontine syndrome (Millard–Gubler syndrome) 
 • Inferior medial pontine syndrome (Foville syndrome) 
 • Ataxic hemiparesis 
 • Cortical blindness (Anton syndrome) 
 • Medial medullary syndrome (Dejerine syndrome) 
• Vertebral artery • Medial medullary syndrome (Dejerine syndrome) 
 • Lateral medullary syndrome (Wallenberg syndrome) 
• Anterior spinal artery • ASAS 
• Posterior spinal artery • PSAS    50 
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Figure 8 
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Management : 
First to recognise even the subtle clinical presentation is very important in the 
management of CVA. Recognising the hemiparesis would not be great deal, but mild 
sensory disturbances, gait disturbances, double vision, blurring of vision, giddiness, 
difficulty in swallowing, seizures in young females, TIA’s, deviation of angle of 
mouth. Detailed history taking including the assessment of risk factors and clinical 
examination is the key in stroke management. 
 
Rapid assessment by various scoring systems gives a broad idea of severity. 
The various scoring systems are NIHSS, mRS. CT plays a important role in 
management of CVA, it helps in ruling  out hemorraghic strokes. Treatment differs 
totally once heamorraghic stroke is ruled out. MRI with MRA with diffusion and 
perfusion weighted image helps in assesing the ischemic penumbra in ischemic stroke, 
which is reversible. 
 
The goals in the initial phase include: 
 
 Attention and protection of airway, breathing, and circulation 
 Assess for any reversible condition which closely mimics stroke 
 Determining eligibility for thrombolytic therapy  
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Routine baseline investigations (TABLE 10): 
Complete haemogram  
Blood sugars Hypo or hyper glycemia 
Urine routine Diabetes , infection 
Serum electrolytes & ABG Hyponatremia or hypokalaemia or hyperkalaemia 
Renal function tests Renal failure 
Fasting lipids Dyslipidemia  
Homocysteine levels Homocystinemia 
Serology  Vasculitis , Infections, HIV, VDRL 
ECG Left ventricular hypertrophy (LVH), Atrial 
fibrillation, arrhythmias, AMI 
Echocardiography Infective endocarditis, atrial myxoma 
ESR, CRP Autoimmune causes-vasculitis, SLE 
To do (optional)  
ANA profile, APLA APLA syndrome, SLE, vasculitis 
Coagulation profile Protein C and S deficiency, anti thrombin III 
deficiency, hyperfibrinogenemia. 
Genetic studies (optional)  CADASIL, MELAS, CARASIL.,etc 
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Diffusion-Weighted� Apparent Diffusion� Perfusion-Weighted� Image�  
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 Patients should be maintained with oxygen if hypoxic and should be maintained at 
94%
52
 
 Differential diagnosis are Migraine aura,seizureswith postictal paresis (Todd’s 
paralysis),aphasia or neglect, CNS tumors or abscess, conversion disorder, 
hypertensive encephalopathy, head trauma, MELAS, multiple sclerosis, PRES, 
Spinal cord disorder such as compressive myelopathy, spinal dural arteriovenous 
fistula , SDH, syncope, systemic infection, Toxic metabolic disturbance such as 
hypoglycemia exogenous drug intoxication, transient global amnesia, viral 
encephalitis, Wernicke’s encephalopathy.  
 To watch for signs of endocarditis, cholesterol emboli, purpura, ecchymoses, or 
evidence of recent surgery or other invasive procedures, particularly if reliable 
history is not forthcoming. The funduscopic examination may be helpful if there 
are cholesterol emboli or papilledema. The head should be examined for signs of 
trauma. A tongue laceration may suggest a seizure. 
  Fluids – most of the patient present with volume depletion, administration of 
isotonic saline is sensible, avoidance of hypotonic solutions is advisable since it can 
worsen cerebral edema. 
 Both hypo and hyperglycemia have poor outcomes, maintaining RBS 140 – 180 mg 
/dl is advisable.
52-57
 
 Supine position is preferred for nonhypoxic patients with acute ischemic stroke 
who are able to tolerate lying flat
52
 
 Patients with AIS, symptoms may be provoked when there is decrease in preload 
Like standing, sitting, or elevating the head of the bed.
 58,59
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 30 degrees head elevation is recommended for patient who are prone for aspiration, 
cardiac and pulmonary issues, elevated intracranial pressure. Otherwise keeping the 
bed flat for 24 hrs. is advised. 
 Hyperthermia worsens ischemic process , therefore it should be controlled with 
antipyretics. 
 According to the latest guidelines when not choosing thrombolytic therapy, the 
blood pressure reduction should be made only when the blood pressure exceeds 
220/120 mmHg or earlier in the following conditions active IHD , heart failure, 
aortic dissection, hypertensive encephalopathy, acute renal failure, or pre-
eclampsia/eclampsia 
60,61
 
 Blood pressure while thrombolysing a patient needs proper management <185 
mmHg of systolic and diastolic of 110 mmHg for at least 24 hrs. .
60,61
 
 
There is some evidence from small randomized controlled trials suggesting that 
early initiation of selective serotonin-reuptake inhibitors (SSRIs) after ischemic stroke 
for patients with hemiparesis but without depression enhances motor recovery and 
reduces dependency 
62,63
. However, it is unclear if this apparent benefit occurs through 
a reduction in poststroke depression or some other mechanism. 
 
Prevention of the following complications: MI, CHF, Dysphagia, Aspiration 
pneumonia, Urinary infection, DVT, Pulmonary embolism, Dehydration, 
Malnutrition, Pressure sores, joint complications and contractures. 
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Figure 13: General approach to anti thrombotic therapy in AIS 
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 Early fibrinolysis : 
 
According to AHA/ASA guidelines for the management of AIS, indications for 
thrombolysing a patient with fibrinolytics to restore the blood flow to the brain and 
early resolution or neurological deficits. For this purpose, most commonly used 
fibrinolytic drug is r-tPA (recombinant tissue plasminogen activator). Streptokinase 
which has a major role in AMI, has high incidence of complications in acute AIS. 
Hence this drug is of not on regular use for AIS
69,70,71
. Individual presented to ED 
must be identified by inclusion and exclusion criteria where patient is a feasible 
candidate for fibrinolysis. They must be thrombolysed within a window period of 
maximum of 4.5hrs from the onset of symptoms.  
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The 0.9 mg per Kg of body weight of rt- PA is approved by FDA.  Firstly, 
bolus of 10% of the dose should be given over one minute, with remaining dose of 
90% to be given over sixty minutes. Weight should be determined reliably.  In a study 
in Japan, treatment with a lower dose of0.6 mg per kilogram r-tPA concluded that it 
had similar efficacy. 3
rd 
generation plasminogen activators, such as tenecteplase and 
desmoteplase, are more fibrin specific than 2
nd
 generations r-tPA and cause less 
activation of systemic complications.
69
 Symptomatic ICH occurs in 1.7 to 8.0% of 
treated patients.
70,71,72,73
Administration of cryoprecipitate and platelets, for 
symptomatic hemorrhage 
74,75,76
 
 
 10 units of cryoprecipitate (to increase fibrinogen and factor VIII 
 
 6-8 units of platelets to be given 
 
 In patient receiving UFH consider giving protamine 1mg for every 100 U UFH 
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INCLUSION AND EXCLUSION CRITERIA FOR THROMBOLYSIS IN AIS:  
 
INCLUSION CRITERIA :  
 
 Onset of symptoms < 3 hours before beginning treatment  
 Onset time is defined as either the witnessed onset of symptoms or the time last 
known normal 
 Age ≥18 years  
 
EXCLUSION CRITERIA  
 Significant head trauma or prior stroke in previous 3 months  
 Symptoms suggestive of any history of haemorrhage stroke 
 Intracranial neoplasm, arteriovenous malformation, or aneurysm  
 Recent intracranial or intra-spinal surgery  
 Arterial puncture at a non compressible site in the last seven days 
 Elevated blood pressure (systolic >185 mm Hg or diastolic >110 mm Hg)  
 Active internal bleeding  
 Blood glucose concentration < 50mg/dl  
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 Acute bleeding diathesis, including but not limited to: Platelet count 
<1,00,000/mm³  
 Heparin received within 48 hours, resulting in abnormally elevated aPTT greater 
than the upper limit of normal  
 Current use of anticoagulant with INR >1.7 or PT >15 seconds and current use of 
direct thrombin inhibitors or direct factor Xa inhibitors with elevated sensitive 
laboratory tests (such as aPTT, INR, platelet count, and ECT; TT; or appropriate 
factor Xa activity assays)  
 CT demonstrates multilobar infarction (hypodensity >1/3 cerebral hemisphere)  
 
RELATIVE EXCLUSION CRITERIA : 
 
 Only minor or rapidly improving stroke symptoms (clearing spontaneously)  
 Seizure at onset with postictal residual neurological impairments  
 Major surgery or serious trauma within previous 14 days  
 Recent gastrointestinal or urinary tract haemorrhage (within previous 21 days)  
 Pregnancy  
 MI in the past three months 
 
To extend IV tPA to 4.5 hours from symptom onset/last known normal, the following 
additional criteria MUST be met:  
 Patient is < 80 years of age  
 Patient does not have a history of both diabetes AND stroke  
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 Patient is not taking Warfarin (Coumadin) or any other anticoagulant regardless of 
INR/coagulation results  
 NIHSS is < 25  
 Written informed consent obtained from patient and/or family – required when IV 
tPA given within the 3-4.5 hour window.  
 
 Anti Coagulants:  
Anticoagulation is not recommended in all the patients with AIS in emergency 
condition. Drugs most commonly used are low molecular weight heparin (LMWH) or 
unfractionated heparin (UFH)
64
. They are to prevent venous thromboembolism. Only 
with following situations, anticoagulation therapy is indicated : 
 Conditions with potential high risk of early cardiogenic reembolization 
 Symptomatic dissection of arteries supplying the brain 
 Symptomatic extra-cranial or intra-cranial atherosclerotic stenosis  
 Basilar artery occlusion before or after intra-arterial pharmacological or 
mechanical thrombolysis 
 Known hypercoagulable states 
 Cerebral venous sinus thrombosis  
 
 Anticoagulants should not be given for 24 hrs. post thrombolysis 
 Early anticoagulation should be avoided when potential contraindications to 
anticoagulation are present, such as a large infarction (NIHSS >15), 
uncontrolled hypertension, or other bleeding conditions. 
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 Anti-thrombotic agents :  
They are mainly used for secondary prevention of stroke. Drugs most 
commonly used are aspirin. Clopidogrel and extender release dipyridamole. Newer 
drugs such dabigatran, apixaban and rivaroxaban are being studied for anticoagulation 
comparing with warfarin for primary end point. According to guidelines, aspirin 
should be given within 48hrs (Preferably within 24 hrs.) of onset of stroke to prevent 
mortality and primary end point.  
 
Endovascular techniques – intra-arterial fibrinolysis, thrombo-embolectomy, 
suction thrombectomy, angioplasty and revascularisation are few among known 
endovascular procedures. The main aim of these is to recanalise the thrombosed vessel 
to improve the blood flow. For this a team of skilled neurologists, interventional 
radiologists, anaesthesiology, nursing and technical support for optimal success.  
 
 
 Neuro protection:  
Several novel neuro-protective agents like citicholine, traxoprodil, ONO-2506, 
magnesium, SSRI, DP-b99g naloxone, gangliosides, nimodipine, N-methyl-D-
aspartate–receptor antagonists, antibodies to adhesion molecules, and free-radical 
scavengers and NXY-059 have been identified. They limit the infarct size and 
improve functional outcome 65. They act as free radicals scavengers and inhibit 
further occurrence of neuronal cell death.  
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 Rehabilitation centres :  
The main aim of these centres is to improve the quality of life of stroke 
survivor by improving the skills to do the daily day to day activities. There were four 
recommendation and they are: 
 
First, diagnostic evaluation, initial treatment, preventive therapy, and 
rehabilitation services should be provided in a coordinated setting.  
 
Second, measures to prevent deep-vein thrombosis should be implemented.  
 
Third, prevention of recurrent stroke and of complications of stroke should be 
given high priority.  
 
Fourth, surveillance for the development of depression is important, since 
major depression occurs in 10 to 30 percent of patients who survive a stroke.
66,67,68
 
Dysphagia, urinary incontinence, immobility, focal weakness, aphasia, a tendency to 
fall, injury to the skin, bowel irregularity or fecal incontinence, and shoulder injury 
have to be assessed and treated. A team of neurologist, psychiatrist, occupational 
therapist, speech language therapists, dietician and social workers play an important 
role in achieving the desired result. 
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RESULTS: 
In this study, about 75 consecutive cases admitted with AIS, which met 
inclusion and exclusion criteria are taken into the study. At presentation, along with 
complete history taking, relevant clinical examination, scoring was done, based on 
NIHSS at admission. 
 
The following objectives were studied : 
 
 Percentages of intracranial, extracranial or both involvement in stroke 
 Percentages of anterior and posterior circulation strokes in PSGIMSR 
 Most commonly involved arteries 
 Correlation of infarcted area in the brain and MRA + CV doppler 
 The acute, chronic or both nature of the brain infarcts 
 Correlation of clinical presentations and infarcted areas 
 Percentages of recurrent CVA 
 Percentages of intracranial anomalies 
 Percentage of thrombolysis in PSGIMSR 
 NIHSS comparisons between right and the left sided brain involvement 
 Percentage of smokers, alcoholics or both  
 Percentages of DM, SHT, Dyslipidemia  
 Incidental ANA-IF positivity and hyperhomocystenemias in PSGIMSR 
 Decision regarding medical or surgical treatment based on the arterial studies 
 Prevention of  strokes 
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GENDER: 
 
Among the study population of 75 patients, 62 (83%) were males and 13 (17%) were 
females suffered with AIS. Males are invariably more in number than females in this 
study.  
 
 
Figure 16 
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AGE:  
Among the age groups involved, most commonly patients were aged more than 50 
years of age group constituting 77% of total patients in this study. Out of which 47 
were males and 11 females. The mean age in this study population was 59 years. The 
young stroke population in this study was 5%.  
 
Table 11: 
 
 
Age Distribution 
        
   
SEX 
    
Age Male Female Total (%) 
< 30 0 0 0 0% 
31 – 40 4 0 4 5% 
41 – 50 11 2 13 18% 
>50 47 11 58 77% 
Total 62 13 75 100% 
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Figure17: Extracranial, intracranial or both  
 
 
In this study of 75 patients,31% of the patients had intracranial obstruction due 
to atherothrombotic process which was classically seen in MRA - IC. Eleven 
percentage of the patients had only extracranial occlusion which was seen in CV 
doppler studies. Twenty one percentage of the study population had both intracranial 
and extracranial leisions and 37% had normal IC & EC studies, probably related to 
small vessel ischemia. Extracranial occulution that carotid artery disease constitutes 
10-20% of the strokes, stroke risk is directly proportional to the degree of occlution. 
Carotid endarterectomy should be considered within 2 weeks if  carotid stenosis of 
more than 70% involvement.There is less benefit of end carotidectomy and carotid 
 56 
stenting in patients with stenosis of  carotids 50 to 69% and in asymptomatic patients, 
and there is literally  no benefit in patients with stenosis of less than 50%.  
 
Figure 18: Anterior and posterior circulation involvement 
 
%
Anterior 
Posterior
37 63
n = 28 n = 47
 
 
 In this study population,fourty seven out of seventy five patients had anterior 
circulation stroke and rest twenty eight patients had posterior circulation involvement. 
All patient was investigated with MRI –MRA IC and CV doppler studies. Thus 
anterior circulation was predominant than posterior circulation. 
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Table 12: Most commonly involved arteries 
 
ASSOCIATION OF AREA OF INFRACT WITH LATERALITY 
 Laterality  
Area 
Right Left Total 
ACA 
1 3 4 
MCA 
24 19 43 
PCA  
14 14 28 
Total 
39 36 75 
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Figure 19: Most commonly involved arteries 
 
 
Among the vascular supply to the brain, the most commonly involved arteries 
in this study population was MCA. Fourty three out of seventy five patients had MCA 
involvement. Among the 43 patient who had MCA involvement, 24 patients had 
involvement in the right side and 19 patients in the left side MCA.PCA was involved 
in twenty eight patients.ACA was involved in 4 patients, since it has a collateral blood 
supply. 
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Figure 20: Correlation of infarcted area in the brain and MRA + C V doppler 
 
CORRELATION OF AREA OF INFARCT AND MRA + C V Doppler 
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Wilcoxon Signed Ranks Test   
 Frequencies 
    N 
Vessel - Infarct Negative Differences
a
 0 
Positive Differences
b
 30 
Ties
c
 45 
Total 75 
a. Vessel < Infarct  
b. Vessel > Infarct   
c. Vessel = Infarct   
 
Test Statistics
b
 
  
Vessel - Infarct 
Z -5.477
a
 
Asymp. Sig. (2-tailed) <0.001 
a. Based on negative ranks. 
b. Wilcoxon Signed Ranks Test 
 
Fourty five out of seventy five patients comprising sixty percentage of the 
study population had positive correlation of location of the infarct in the brain and 
either MRA & C –V Doppler findings. Thirty seven percentage of the study 
population had normal MRA & C-V Doppler findings. Only in 3% of the study 
population there was no correlation of the same. The normal study of the vessels are 
included in the positive differences. 
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Figure 21: The acute, chronic or both natures of the brain infarcts 
 
 
 
 
Among the study population eighty three percentage of the population had 
acute infarct in the brain and remaining seventeen percentage had both acute & 
chronic infarcts. Sixty two out of seventy five patients had acute infarcts and 
remaining thirteen patient had both acute and chronic infarcts in the brain. 
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Table 13: Clinical Presentations 
 
HEADACHE 6 
SLURRING OF SPEECH 33 
GAIT 16 
GUIDINESS 17 
DEVIATION OF MOUTH 33 
WEAKNESS  51 
VOMITING 8 
URINARY INCONTINENCE 1 
DECREASED SENSATION 12 
TOTAL LOSS OF SPEECH 4 
DOUBLE VISION 5 
HICCUPS 1 
BLURRING OF VISION 1 
ALTERED SENSORIUM 1 
SEIZURES 3 
PIN PRICK SENSATION 1 
PAIN 1 
DYSPHAGIA 1 
LOC 2 
TINGLING SENSATION 1 
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The most common symptoms was weakness, slurring of speech, deviation of 
angle of Mouth, gait disturbances, giddiness and decreased sensation. Other symptoms 
were headache, seizures, vomiting, headache, loss of consciousness, loss of speech, 
pain, dysphagia, double vision, blurring of vision, hiccups, altered sensorium, 
incontinence. Mainly to differentiate between anterior vs. posterior circulation with 
history, following symptoms are very specific for posterior circulation stroke if 
present. 
 
The symptoms, which are specific for posterior circulation involvement, are 
vomiting, giddiness, gait disturbances, double vision. Presentations with seizures 
mostly had cortical involvement. The non specific symptoms which poorly indicates 
whether it is anterior or posterior involvement are sensory symptoms, weakness and 
slurring of speech. 
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Figure 22: Correlation of clinical presentations and infarcted areas 
 
 
93%
7%
CORRELATION OF CLINICAL 
PRESENTATION AND INFARCTED AREAS 
OF BRAIN(%)
Yes
No
n 
n = 70
 
CORRELATION OF CLINICAL VS AREA OF INFARCT 
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Wilcoxon Signed Ranks Test 
Frequencies 
    N 
Area - Clinical Negative 
Differences
a
 0 
Positive 
Differences
b
 5 
Ties
c
 70 
Total 75 
a. Area < Clinical  
b. Area > Clinical   
c. Area = Clinical   
 
Test Statistics
b
 
  
Area - Clinical 
Z -2.236
a
 
Asymp. Sig. (2-tailed) <0.05 
a. Based on negative ranks. 
b. Wilcoxon Signed Ranks Test 
 
The clinical presentations was correlating with infarct in MRI in seventy of 
seventy five patient in this study population which constitute 93 percentage. Only 
seven percentage of the study population there was no correlation due to bilateral 
involvement. 
 66 
 
Figure 23: Percentages of recurrent CVA 
 
17%
83%
Percentage of recurrent CVA
Recuurent
First episode
n = 62
n = 13
 
 
In this study population, percentage of recurrent CVA was nearly 17%which 
accounted for thirteen out of seventy five patients. The cause for recurrent CVA was 
smoking, alcohol and poor compliance of medications. The mean age of recurrent 
CVA was 62 yrs and average NIHSS was 6.5 which was significantly higher than 
patients who had CVA for the first time. 
 
Relapse of alcohol, hard to kickoff smoking, poor adherence of medications 
was prime important in the stroke recurrence. Nicotine patches, chewing gums which 
had nicotine, psychiatric counseling  and rehabilitation to prevent alcohol relapse.  
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Figure 24: Percentages of intracranial anomalies 
 
 
 
In the study population, 2 patients which constitutes of 3% had congenital 
anomalies. They were Frontal arteriovenous malformation and fetal PCA. 
 
Figure 25: Percentage of thrombolysis in PSGIMSR 
 
 
In this study poppulation none of the patients was thrombolysed. 
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Figure 26: NIHSS comparisons between right and the left sided brain 
involvement 
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Mean NIHSS score with Laterality  
 
      
95% CI for 
Mean       
  Mean SD Lower Upper Minimum Maximum Sig 
Right 5.5 2.9 4.5 6.5 1 11   
Left 5.2 2.3 4.4 6.0 1 10 < 0.05 
Bilateral 4.8 3.3 2.0 7.5 2 12   
Total 5.3 2.7 4.7 5.9 1 12   
 
In this study population NIHSS was more in right sided brain involvement 
when compared with left and bilateral involvement. The average NIHSS for right, left, 
bilateral invelvement was 5.5, 5.2, 4.8 respectively. The maximum NIHSS in this 
study population was 12 which was in the bilateral involvement. 
 
Figure 27: Percentage of smokers, alcoholics or both  
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The percentage of smokers, alcoholics and both was 17%, 5%  and 24% 
respectively. When put together totally 46% of the study population was abusing 
either alcohol, tobacco or Both. 
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Figure 28: Percentages of DM, SHT, Dyslipidemia  
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In this study population the percentage of  diabetic mellitus type 2, systemic 
hypertension, dyslipidemic, DM + systemic hypertension was 11%, 9%, 35% and 
41% respectively. Totally 61% of the study population was either DM or hypertensive 
or both. The percentage of dyslipidemia was 35% for this study population. 
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Figure 29 & 30: Incidental ANA-IF positivity and hyperhomocystenemias in 
PSGIMSR 
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Total of fourty six patients was studied with fasting serum homocystiene and 
ANA –IF. This blood sample was taken along with other investigations to prevent 
extra needle prick which would lead to inconvenience. Vitamins such as B12,B6 and 
folate play a vital role in the homocystiene methionine cycle, thus alcholics commonly 
have lower levels on folate and hence the increased homocystiene levels. Serum 
homocystiene was done in patients irrespective of any connective tissue disorder 
history. In this study population increased homocystiene and incidental ANA –IF 
positivity was 54% and 24% respectively. Serum homocystiene was elevated in 36% 
of the alcoholics and 64 % of non alcoholics. The highest value was 160 against <12 
of the normal reference range. Serum homocystiene was elevated in acute stroke, 
there is correlation made in few studies that higher the homocystiene calues higher the 
mortality and recurrence of stroke. Incidental ANA- IF positivity in 24% of the study 
population raises concern whether it should be done routinely in all stroke patients and 
the same should be repeated to confirm the autoimmune etiology 6 weeks later. 
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Figure 31: Decision regarding medical or surgical treatment based on the arterial 
studies 
 
 
 
 
Prevention of  strokes :  
 
Stroke prevention have to be endorsed at all levels primary, secondary and 
tertiary levels. Primary prevention is by banning of tobacco and alcohol and stop 
abusing the same.  
 
Secondary prevention is by controlling hypertension, DM, lipids and taking 
antiplatelets dietary modification, exercise and statin therapy. Tertiary prevention is 
prevention of diabilty of stroke. Identifying the etiology play an important role in the 
prevention of strokes, especially the cardioembolic strokes. The use of oral 
anticoagulants play a important role in prevention of CVA. 
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DISCUSSION 
 
Stroke among adults rapidly increasing in the recent times. Proper clinical 
history, risk factors, investigations, proper management of stroke is the need of the 
hour for AIS patients.In this study, 75 patients of acute ischemic stroke: 
 
 Male population was more when compared with females. 
 The mean age was 59 years 
 Predominantly anterior circulation was involved 
 Right MCA was the most common artery involved 
 Positive correlation for clinical presentation and area of infarct 
 Positive corelation for areas of infarct and the vessels involved 
 Most common clinical presentation was weakness and slurring of speech 
 3% intracranial anamolies 
 Smoking, alcoholism and dyslipidemia have been found to be significantly 
associated with stroke and its recurrence.  
 Poor control of DM, systemic hypertension was associated with sroke 
recurrence 
 Hyper-homocystinemia has significant association with the causation of stroke. 
56% (only in 46 patients) had significantly elevated levels of homocystiene. 
The levels ideally have to be assessed 6 weeks later, for ideally diagnosing 
hyperhomocystinemia. 
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 The proportion of elevated levels of homocystiene was more in the non 
alcoholics when compared with alcoholics. 
 24% had incidental ANA- IF positivity (out of 46 patientts) but none of them 
had history of connective tissue disease. This incidental finding have to 
rechecked 6 weeks later. 
 Recurrence of stroke though was seen in 17%, but no mortality and less 
morbidity has been observed among these patients. NIHSS was comparatively 
higher than patients who had stroke for the first time. 
 None of the pateints was thrombolysed due to varied reasons like exclusion 
criteria, after explaining the risks involved and mainly the time lapse in 
reaching the hospital. 
 Right sided infarct had higher NIHSS  
 None of the patients was treated surgically. 
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CONCLUSION  
 
I thank PSGIMSR for the grant of one lakh Rupees for the study of ANA- IF 
and serum Homocystiene in AIS patients. Good clinical examination plays a 
important role in localising the leision despite many caveats. 
 
 Positive correlation for clinical presentation and area of infarct 
 Positive corelation for areas of infarct and the vessels involved 
 Elevated serum homocystiene and Incidental positivity of ANA-IF have to 
reassessed 6 weeks later. 
 Awareness regarding golden time have to made available among the masses 
 It is team work rather one person job required in the management of AIS 
patients. 
 Prevention at every levels is important, Prevention is always better than cure. 
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PROFORMA 
 Name  
 Age 
 Sex 
 Address  
 Occupation  
 Chief  complaints 
 H/o cocaine abuse  or  any  other  substance  abuse  or  use  of  oral  contraceptives 
 H/o  smoking,  alcohol,  diabetes,  hypertension,  seizure  disorder, bleeding  
disorders,  migraine, thrombosis,  rheumatic  heart  disease,  ischaemic  heart  
disease,  severe  LV  dysfunction, arrhythmias (mainly  atrial  fibrillation) 
 H/o  head  trauma  
 Family  history  of  thrombosis,  hyperlipidaemia,  hypertension, diabetes 
 
CLINICAL EXAMINATION 
 
 General examination 
 CNS examination: 
o Speech – dysarthria or aphasia (motor / sensory/ global) 
o Cranial nerves 
o Weakness of limb – 1 UL or 1 UL and 1 LL or 4 limbs 
o Power – UL and LL 
o Sensory  
o Cerebellar  
o Carotid and subclavian bruits, murmurs 
o Peripheral pulses 
o NIHSS on admission 
o mRS on admission and after 3 months 
 
 Routine investigations: 
 
o Complete blood count, Diabetic profile 
o Serum electrolytes, urine routine and microscopy 
o ECG, ECHO, serum homocysteine levels 
o CT- brain plain, MRI brain with angiography 
 
 Other investigations: 
o ANA IF and Antiphospholipid antibodies  
 
 If needed:  
o Complete coagulation work up 
o Genetic testing 
 
  
ABBREVIATIONS 
 
AIS – Arterial ischemic stroke 
WHO - World  Health  Organization  
TOAST - Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. 
ANA – Anti nuclear antibody profile 
APLA – Anti-phospholipid antibody 
CT – Computed tomography 
MRI – Magnetic resonance imaging  
NIHSS - National  Institute  of  Health  stroke  scale 
mRS – modified rankin scoring 
TIA - Transient ischemic attacks  
DALY - disability life adjusted years  
LDL-C - low-density lipoprotein cholesterol  
TGL - Triglycerides  
HDL-C - High-density lipoprotein cholesterol (HDL-C) 
BMI – Body mass index 
SBP – Systolic blood pressure 
DBP – Diastolic blood pressure 
FBS - fasting blood glucose 
HbA1c - glycosylated haemoglobin  
DM – Diabetes mellitus 
MA – Migraine headache with aura  
ECMO – Extracorporeal membrane oxygenation 
RHD - Rheumatic heart disease 
DCM - Dilated cardiomyopathy  
AMI – Acute myocardial infarction 
IE – Infective endocarditis 
AF – Atrial Fibrillation  
CAD – Coronary artery disease  
LVH – Left ventricular hypertrophy 
LAE – Left atrial enlargement  
CBS – Cystathione b-synthase 
PV – Polycthemia vera 
ET - Essential thrombocythemia  
PAN – Polyarteritis nodosa  
WG – Wegener’s granulomatosis  
CNS - Central nervous system  
CADASIL – Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy 
CARASIL – Cerebral autosomal recessive arteriopathy with subcortical infarcts and 
leukoencephalopathy 
MELAs – Mitochondrial myopathy, encephalopathy, lacto-acidosis and stroke 
EDS – Ehlers Danlos syndromes  
OI – Osteogenenis imperfect  
ADPKD - Autosomal dominant polycystic kidney disease (ADPKD) 
LDS - Loeyz Dietz syndrome  
AD – Autosomal dominant 
COW – Circle of willis 
ACA – Anterior cerebral artery 
MCA – Middle cerebral artery 
PCA – Posterior cerebral artery 
UMN – Upper motor neuron type  
ED – emergency department 
HIV – human immunodeficiency virus 
ECG – Electrocardiogram 
ECHO – Echocardiography 
AHA/ASA – American heart association / American stroke association 
r-tPA – Recombinant tissue plasminogen activator 
NINDS – National institute of Neurological Disorders and Stroke 
aPTT – Activated partial thromboplastin time  
INR – International normalised ratio 
PT – Prothrombin time 
UFH – Unfractionated heparin 
LMWH – Low molecular weight heparin 
DWI - Diffusion weighted image  
PWI - Perfusion weighted image 
PCI - Posterior circulation infarct 
ACI - Anterior circulation infarct 
TCD - Transcranial doppler 
ADC - Apparent diffusion coefficient 
FLAIR - Fluid-attenuated inversion recovery 
SWI - Susceptibility weighted imaging 
ICA - Internal carotid artery 
SCA - Superior cerebral artery 
BA - Basilar artery 
AICA - Anterior inferior cerebellar artery 
PICA - Posterior inferior cerebellar artery 
V1–V4 - Segments of the vertebral artery 
VDRL - Veneral disease research laboratory 
SSRI  - Selective serotonin-reuptake inhibitors  
ED - Emergency department 
MTT - Mean transit time  
CBV - Cerebral blood volume  
CBF - Cerebral blood flow  
IC - Intracranial  
EC - Extracranial 
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I / We (write name of the investigator(s) here), Dr.SRINIVASAN .T V, am carrying 
out a study on the topic: A PROSPECTIVE STUDY OF ETIOLOGY AND 
CORRELATION OF CLINICAL FEATURES WITH MRI-MRA & CAROTID 
VENOUS DOPPLER IN ISCHEMIC STROKE PATIENTS as part of my / our 
research project being carried out under the aegis of the Department of: GENERAL 
MEDICINE  
(Applicable to students only): My / our research guide is: Dr.SUJITH KUMAR S MD, 
Co-guide: Dr.MADAKASIRA BHEEMARAO PRANESH R 
Dr.GNANASHANMUGAM 
The justification for this study is:  
 
Considering the disease burden and the morbidity and mortality associated with 
ischemic stroke in patients,to analyse whether strokes are intracranial or extracranial 
in origin by MRI-MRA & CV DOPPLER and whether to manage medically or 
surgically 
 
The objectives of this study are:  
 
Primary Objective: To study whether strokes are intracranial, extracranial or both in 
origin. 
Secondary Objective: To analyse which areas of the brain is most commonly affected. 
To determine clinical correlation with the area of infarct in the brain. 
 
Sample size: 75  
 
Study volunteers / participants are (specify population group & age group): Patients 
admitted with ischemic stroke. 
 
Location: PSG Hospitals, Coimbatore.  
 We request you to kindly cooperate with us in this study. We propose collect 
background information and other relevant details related to this study. We will be 
carrying out:  
 
Initial interview (specify approximate duration):_____40_____ minutes.  
 
Data collected will be stored for a period of __TWO__ years. We will / will not use 
the data as part of another study. 
 
Health education sessions: Number of sessions: _____________. Approximate 
duration of each session:  
 
______________ minutes.  
 
Clinical examination (Specify details and purpose): To assess the general condition 
and systemic examination 
 
No. of times examined: ONCE  
 
Whether blood sample collection is part of routine procedure or for research (study) 
purpose: NIL 
 
1. Routine procedure 2. Research purpose  
 
Specify purpose, discomfort likely to be felt and side effects, if any: __NIL___ 
 
Whether blood sample collected will be stored after study period:  No, it will be 
destroyed 
 
Whether blood sample collected will be sold:  No  
 
Whether blood sample collected will be shared with persons from another institution:
  No 
 
Medication given, if any, duration, side effects, purpose, benefits: NIL 
 
Benefits from this study: A PROSPECTIVE STUDY OF CORRELATION OF 
CLINICAL FEATURES, MRI-MRA, CAROTID VENOUS DOPPLER IN 
ISCHEMIC STROKE PATIENTS. 
Risks involved by participating in this study: NIL 
 
How the results will be used: Study will be submitted to Dr. MGR Medical 
University as thesis in post graduate course in general medicine.  
 
If you are uncomfortable in answering any of our questions during the course of the 
interview, you have the right to withdraw from the interview / study at anytime. 
You have the freedom to withdraw from the study at any point of time. Kindly be 
assured that your refusal to participate or withdrawal at any stage, if you so decide, 
will not result in any form of compromise or discrimination in the services offered nor 
would it attract any penalty. You will continue to have access to the regular services 
offered to a patient. You will NOT be paid any remuneration for the time you spend 
with us for this interview / study. The information provided by you will be kept in 
strict confidence. Under no circumstances shall we reveal the identity of the 
respondent or their families to anyone. The information that we collect shall be used 
for approved research purposes only. You will be informed about any significant new 
findings - including adverse events, if any, – whether directly related to you or to 
other participants of this study, developed during the course of this research which 
may relate to your willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to 
me, and has been explained to me by the investigator/s. Having understood the same, I 
hereby give my consent to them to interview me. I am affixing my signature / left 
thumb impression to indicate my consent and willingness to participate in this study 
(i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
Signature of the Interviewer with date:      Witness: 
 
Contact number of PI: 08754189611 
 
Contact number of Ethics Committee Office:  0422 2570170 Extn.: 5818 
 
 
 
 
´ôÒ¾ø ÀÊÅõ 
              §¾¾¢ : 
 
  ¬¸¢Â ¿¡ý, PSG ÁÕòÐÅì ¸øæÃ¢Â¢ý 
 Ð¨ÈÂ¢ý ¸£ú, 

 ±ýÈ ¾¨ÄôÀ¢ø ¬ö× §Áü¦¸¡ûÇ 
)û§Çý. 
 
±ý ¬ö× ÅÆ¢¸¡ðÊ:  
 
¬ö× §Áü¦¸¡ûÅ¾ü¸¡É «ÊôÀ¨¼: 
 
 
 
¬öÅ¢ý §¿¡ì¸õ: 
 
 
 
¬öÅ¢ø ÀíÌ ¦ÀÚõ ¿À÷¸Ç¢ý ±ñ½¢ì¨¸: 
 
¬ö× §Áü¦¸¡ûÙõ þ¼õ: 
 
¬öÅ¢ý ÀÄý¸û: 
 
 
 
¬öÅ¢É¡ø ²üÀÎõ «¦ºª¸Ã¢Âí¸û / Àì¸ Å¢¨Ç×¸û: 
 
  
 
 
þó¾ ¬öÅ¢ø ¸¢¨¼ìÌõ ¾¸Åø¸û  ÅÕ¼í¸û À¡Ð¸¡ì¸ôÀÎõ. þ¨Å §ÅÚ 
±ó¾ ¬öÅ¢üÌõ ÀÂýÀÎò¾ô À¼ Á¡ð¼¡Ð. ±ó¾ ¿¢¨ÄÂ¢Öõ )í¸¨Çô ÀüÈ¢Â ¾¸Åø¸û 
Â¡ÕìÌõ ¦¾Ã¢Å¢ì¸ôÀ¼ Á¡ð¼¡Ð. «¨Å þÃ¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ. 
 
þó¾ ¬öÅ¢ø Àí§¸ü¸ ´ôÒì¦¸¡ûÙÅ¾¡ø ±ó¾ Å¢¾Á¡É ÀÄÛõ )í¸ÙìÌì ¸¢¨¼ì¸¡Ð. 
±ó¾ §¿Ãò¾¢ø §ÅñÎÁ¡É¡Öõ ¬öÅ¢Ä¢ÕóÐ Å¢Ä¸¢ì¦¸¡ûÙõ )Ã¢¨Á )í¸ÙìÌ )ñÎ. 
¬öÅ¢Ä¢ÕóÐ Å¢Ä¸¢ì¦¸¡ûÅ¾¡ø )í¸ÙìÌ «Ç¢ì¸ôÀÎõ º¢¸¢î¨ºÂ¢ø ±ó¾ Å¢¾ Á¡üÈÓõ 
þÕì¸¡Ð.  
 
þó¾ ¬Ã¡öîº¢ì¸¡¸ )í¸Ç¢¼õ º¢Ä §¸ûÅ¢¸û §¸ð¸ôÀÎõ / º¢Ä þÃò¾ Á¡¾¢Ã¢¸û «øÄÐ 
¾¢Í Á¡¾¢Ã¢¸û ±Îì¸ôÀÎõ. 
 
§ÁÖõ, þó¾ ¬öÅ¢ø ÀíÌ ¦¸¡ûÅÐ )í¸û ¦º¡ó¾ Å¢ÕôÀõ. þ¾¢ø ±ó¾ Å¢¾ì ¸ð¼¡ÂÓõ 
þø¨Ä. ¿£í¸û Å¢ÕôÀô Àð¼¡ø, þó¾ ¬öÅ¢ý ÓÊ×¸û )í¸ÙìÌò ¦¾Ã¢Âô ÀÎò¾ôÀÎõ. 
 
 
¬öÅ¡ÇÃ¢ý ¨¸¦Â¡ôÀõ  :  
§¾¾¢     :       
 
 
¬ö×ìÌðÀÎÀÅÃ¢ý ´ôÒ¾ø: 
 
¿¡ý þó¾ ¬Ã¡öîº¢Â¢ý §¿¡ì¸õ ÁüÚõ «¾ý ÀÂýÀ¡ðÊ¨Éô ÀüÈ¢ ¦¾Ç¢Å¡¸×õ, 
Å¢Çì¸Á¡¸×õ ¦¾Ã¢ÂôÀÎò¾ô ÀðÎû§Çý. þó¾ ¬Ã¡öîº¢Â¢ø ÀíÌ ¦¸¡ûÇ×õ, þó¾ 
¬Ã¡öîº¢Â¢ý ÁÕòÐÅ Ã£¾¢Â¡É ÌÈ¢ôÒ¸¨Ç ÅÕõ ¸¡Äò¾¢Öõ )À§Â¡¸ôÀÎò¾¢ì ¦¸¡ûÇ×õ 
ÓØ ÁÉÐ¼ý ºõÁ¾¢ì¸¢§Èý. 
 
 
 
¬ö×ìÌðÀÎÀÅÃ¢ý ¦ÀÂ÷, Ó¸ÅÃ¢ : 
 
 
     ¨¸¦Â¡ôÀõ :       
       §¾¾¢ : 
 
 
¬öÅ¡ÇÃ¢ý ¦¾¡¨Ä§Àº¢ ±ñ: 
 
ÁÉ¢¾ ¦¿È¢Ó¨Èì ÌØ «ÖÅÄ¸ò¾¢ý ¦¾¡¨Ä§Àº¢ ±ñ: 0422 2570170   Extn.: 5818 
S.NO SEX AGE NIHSS
correlation of 
clinical vs MRI
correlation of MRI 
with MRA & CVD
DIABETIC S.HTN ANA HOMOCYSTIENE RISK FACTORS
1 M 50 4 Yes Yes DM NIL SMOKER & ALCOHOLIC
2 M 86 5 Yes Yes DM HTN Nil
3 M 57 2 Yes NO NIL NIL SMOKER,
4 M 63 2 Yes NO DM HTN smoker,
5 M 64 4 Yes Yes DM HTN NIL
6 F 50 2 Yes Yes DM HTN NIL
7 F 61 6 Yes Yes DM NIL NIL
8 M 58 2 Yes NO DM NIL SMOKER ALCOHOLIC
9 M 60 4 Yes Yes NIL HTN NIL
10 M 55 9 NO NO NIL NIL ALCOHOL
11 M 76 1 Yes Yes NIL NIL SMOKER
12 M 71 1 Yes Yes NIL NIL Nil
13 F 58 8 Yes Yes DM HTN NIL
14 M 68 3 Yes Yes DM HTN NIL
15 M 70 5 Yes Yes DM HTN NIL
16 M 52 2 Yes Yes NIL NIL ALCOHOLIC,SMOKER
17 M 57 1 Yes NO NIL NIL SMOKER
18 M 63 4 NO Yes DM HTN SMOKER
19 F 54 6 Yes NO DM HTN POSITIVE 29 Nil
20 F 71 7 Yes NO DM HTN NEGATIVE 8 Nil
21 M 47 6 NO NO DM HTN NEGATIVE 10 SMOKER ALCOHOLIC
22 M 66 4 Yes Yes NIL NIL POSITIVE 34 EX SMOKER 
23 M 58 7 Yes Yes NIL NIL NEGATIVE 68 SMOKER
24 m 79 11 Yes NO DM HTN ANA IF NEGATIVE H -22.72 alcholic
25 M 60 6 Yes Yes NIL HTN ANA IF NEGATIVE H -17.9 ALCOHOLIC,SMOKER
26 M 70 5 Yes Yes NIL HTN ANA IF NEGATIVE HC 18 ALCOHOLIC,SMOKER
27 M 52 7 Yes NO DM HTN ANA IF NEGATIVE 32 ALCOHOLIC,SMOKER
28 M 63 6 Yes Yes DM NIL ANA POSITIVE HC 12 EX SMOKER 
29 M 69 10 Yes Yes DM HTN EX SMOKER 
30 M 59 2 Yes NO DM HTN SMOKER ALCOHOLIC
31 M 54 8 Yes NO DM NIL NIL
32 M 64 9 Yes Yes DM HTN SMOKER ALCOHOLIC
33 M 47 1 Yes NO DM HTN NIL
34 M 31 3 Yes Yes NIL NIL NIL
35 m 52 7 Yes Yes NIL NIL NEGATIVE 27 SMOKER ALCOHOLIC
36 M 55 6 Yes NO NIL NIL NEGATIVE 20 Nil
37 F 70 2 Yes NO DM HTN NEGATIVE 5.85 Nil
38 M 43 4 Yes Yes NIL HTN NEGATIVE 95 SMOKER ALCOHOLIC
39 M 45 8 Yes NO NIL NIL NEGATIVE 160 NIL
40 M 72 7 Yes Yes DM HTN NEGATIVE 7.88 Nil
41 M 46 7 NO Yes DM HTN NEGATIVE 14.8 NIL
42 F 60 4 Yes Yes DM HTN negative 16.1 Nil
43 F 47 3 Yes NO NIL NIL positive 21 NIL
44 M 75 8 Yes Yes DM HTN NEGATIVE 14 Nil
45 M 61 8 Yes NO DM HTN POSITIVE 15 Nil
46 M 69 5 Yes NO DM HTN POSITIVE 13 SMOKER
47 M 58 4 Yes NO NIL HTN NEGATIVE 22 Nil
48 M 30 4 Yes Yes NIL NIL NEGATIVE 61 Nil
49 M 32 7 Yes Yes NIL NIL NEGATIVE 19.8 Nil
50 M 70 5 Yes Yes NIL NIL NEGATIVE 19 SMOKER
51 M 50 4 Yes NO DM S.HTN POSITIVE 19 Nil
52 M 73 10 Yes Yes DM S.HTN sample rec 19 NIL
53 F 58 9 Yes Yes NIL NIL NEGATIVE 5.9 Nil
54 M 61 8 Yes NO NIL NIL NEGATIVE 81 NIL
55 M 50 4 Yes Yes DM NIL ALCOHOL
56 M 48 12 Yes Yes DM HTN NEGATIVE 6 ALCOHOLIC,SMOKER
57 M 67 5 Yes Yes NIL NIL NEGATIVE 10 NIL
58 M 58 3 Yes NO NIL NIL NEGATIVE 16 NIL
59 M 60 3 Yes NO NIL NIL NEGATIVE 32 ALCOHOLIC,SMOKER
60 F 62 6 Yes Yes DM HTN POSITIVE 15 NIL
61 M 54 5 Yes Yes DM HTN NEGATIVE 16 ALCOHOLIC,SMOKER
62 M 52 5 Yes NO DM HTN Nil
63 M 74 9 Yes Yes NIL HTN POSITIVE 44 alcholic
64 M 46 10 Yes Yes DM HTN NEGATIVE 24 ALCOHOLIC,SMOKER
65 M 69 4 Yes NO NIL NIL POSITIVE +++ 51 NIL
66 M 65 10 Yes Yes DM NIL NEGATIVE 21 ALCOHOLIC,SMOKER
67 M 45 2 Yes NO NIL NIL NEG 50 ALCOHOLIC,SMOKER
68 F 80 2 Yes NO DM Nil NEG 13 Nil
69 F 65 3 Yes NO NIL HTN POSITIVE ++ 20 Nil
70 M 35 5 Yes Yes NIL NIL NEG 13 SMOKER
71 M 74 3 Yes NO DM NIL NEG 12 NIL
72 F 79 7 Yes Yes NIL HTN NEGATIVE 32 NIL
73 M 64 4 NO Yes DM HTN SMOKER
74 M 39 6 Yes Yes NIL NIL ALCOHOLIC,SMOKER
75 M 5 Yes Yes NIL NIL ALCOHOLIC,SMOKER
